RxDoctor Payments Data

Victor Abraham, MD

Urology · Wilmington, NCNPI 1003848540

Payments from drug & device makers

$4,508in general payments, 2019–2025

Across 161 payments — averaging $28.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Neotract Inc.$666
  • Johnson & Johnson$375
  • Endo Pharmaceuticals Inc.$367
  • Pfizer$322
  • Urogen Pharma, Inc.$281
  • plus $1K from 25 others

What the payments were for

  • Travel & lodging$3257%
  • Food & beverage$3,80484%
  • Education$3798%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,508 in reported general payments places this provider in the 60th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$363,700
Medicare patients
904
Services billed
108,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$155,440
GemtesaVibegron33$29,634
MyrbetriqMirabegron14$13,172
Tamsulosin Hcl586$10,954
Silodosin47$4,071
Dutasteride113$3,709
Potassium Citrate ErPotassium Citrate16$2,664
Testosterone11$2,342
Testosterone Cypionate52$2,202
Finasteride77$1,332
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst49$1,252
Estradiol13$929
Oxybutynin Chloride ErOxybutynin Chloride51$867
Solifenacin Succinate14$303
Ciprofloxacin Hcl69$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,412$168,61325 claims
Sumitomo Pharma America, Inc.Gemtesa$73$29,63433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 urology providers in North Carolina.

Other urology in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →